Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases

A technology for nervous system diseases and protopanaxadiol, which is applied in the field of medical applications, can solve the problems of less research on ginsenosides and less reports on the pharmacological activity of nervous system diseases.

Inactive Publication Date: 2011-04-20
王泽君
View PDF0 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there have been many studies on ginsenosides with sugar groups, there are few studies on ginsenosides, and there are few reports on the pharmacological a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases
  • Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases
  • Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Embodiment one: the preparation of PPD, PPT, ginsenoside mixture tablet and compound tablet

[0070] 1. PPT tablet prescription (1000 tablets):

[0071]

[0072] Prepared using common techniques.

[0073] 2. PPT tablet prescription (1000 tablets):

[0074]

[0075]

[0076] Prepared by usual techniques.

[0077] 3. PPD tablet prescription (1000 tablets)

[0078]

[0079] Prepared by usual techniques.

[0080] 4. Ginsenogenin mixture (1000 tablets):

[0081]

[0082] Prepared by usual techniques.

[0083] 5. Compound prescription for PPT tablets (1000 tablets)

[0084]

[0085] Prepared by usual techniques.

Embodiment 2

[0086] Embodiment two: the preparation of PPT, PPD, ginsenoside mixture capsule

[0087] 1. PPT capsule prescription (1000 capsules):

[0088] PPT 500g

[0089] Magnesium Stearate Appropriate amount

[0090] Lactose 30-120g

[0091] Prepared by usual techniques.

[0092] 2. PPD capsule prescription (1000 capsules):

[0093] PPD 500g

[0094] Starch 50-200g

[0095] Magnesium Stearate Appropriate amount

[0096] Prepared by usual techniques.

[0097] 3. Weigh 250g of PPT, and prepare hard capsules containing 250mg of PPT in each capsule with the method of prescription 1.

[0098] 4. Ginsenogenin mixture capsule prescription (1000 capsules):

[0099] Ginsenogen Mixture 500g

[0100] Magnesium Stearate Appropriate amount

[0101] Lactose 30-120g

[0102] Prepared by usual techniques.

Embodiment 3

[0103] Example Three: Preparation of PPT, PPD and Ginsenogen Mixture Injection

[0104] 1. PPT injection prescription:

[0105] PPT 250g

[0106] Tween 80 25-80g

[0107] Prepared by usual techniques. Add 1000ml of water for injection, stir to dissolve completely, filter, potting, sterilization, light inspection, packaging to make each tube containing 0.5g / 2ml of PPT.

[0108] 2. PPD injection prescription:

[0109]

[0110] Prepared by usual techniques.

[0111] 3. Prescription of ginsenogenin mixture injection: Weigh 250g of ginsenogenin mixture, and prepare it in the same way as in prescription 2, so that each tube contains 0.5g / 2ml of ginsenogenin mixture.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and/or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.

Description

Technical field: [0001] The invention relates to the field of medical applications. Specifically, the present invention relates to the medical application of protopanaxatriol, protopanaxadiol and their mixtures in nervous system diseases, preferably in the treatment and / or prevention of epilepsy, cerebral ischemic disease, learning and memory disorders, Applications for Parkinson's disease. Background technique: [0002] Ginsenosides are mainly distributed in various plants such as Araliaceae Panax and Cucurbitaceae Gynostemma Gynostemma, and are considered to be the main active ingredients in plants such as Ginseng. Asian ginseng and American ginseng (Panax ginseng and Panax quinquefolius) are two types of plants commonly used for medicinal ginseng. The traditional Chinese medicine ginseng first appeared in "Shen Nong's Materia Medica" and was listed as the top grade. It is said that it "mainly nourishes the five internal organs, calms the spirit, calms the soul, relieves...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/575A61P25/00A61P25/08A61P9/10A61P25/28A61P25/16A23L1/30A23L33/10
Inventor 王泽君葛凯勤孙黎勤王勤科
Owner 王泽君
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap